TEVA-LOSARTAN/HCTZ (2019-03-06)

Report a Concern (http://www.healthycanadians.gc.ca/report-signalez/index-eng.php)

Starting date:	March 6, 2019
Type of communication:	Drug Recall
Subcategory:	Drugs
Hazard classification:	Type I
Source of recall:	Health Canada
Issue:	Product Safety
Audience:	General Public, Healthcare Professionals, Hospitals
Identification number:	RA-69266

- Reason
- Depth of distribution
- Affected products

Recalled Products

Teva-Losartan / HCTZ 50/12.5mg Tablet

Reason

Affected lots manufactured with an API that may contain the impurity N-nitroso-N-methyl-4-aminobutyric acid (referred as “NMBA”) above the acceptable level.

Depth of distribution

Retailers

Affected products

Teva-Losartan / HCTZ 50/12.5mg Tablet

DIN, NPN, DIN-HIM

DIN 02358263

Dosage form

Tablet

Strength

Hydrochlorothiazide 12.5mg
Losartan potassium 50.0mg

Lot or serial number

35344801A, 35349397A

Companies

Recalling Firm	Teva Canada Ltd. 30 Novopharm Court Toronto M1B 2K9 Ontario CANADA
Marketing Authorization Holder	Teva Canada Ltd. 30 Novopharm Court

Toronto
M1B 2K9
Ontario
CANADA

Date modified: 2019-03-11